Key

Inclusion Criteria:

- Patient at least 18 years of age with stage II or III multiple myeloma

- One or more lytic bone lesions

- If currently receiving bisphosphonate therapy, have been on a stable dose for ≥ 2
months before dosing day 1 or must not have received bisphosphonates within 2 months
of dosing day 1

- If patient has undergone previous autologous or allogenic hematopoietic stem cell
transplantation (HSCT), they must be stable (in the opinion of the investigator) and
be a minimum of 6 months since HSCT

- Has planned HSCT for the duration of the study

- Has moles or lesions that are currently undiagnosed, but are suspect for malignancy

- Has an underlying condition that may result in abnormal bone metabolism other than
cancer related bone lesions, such as a history of hyperparathyroidism,
hypoparathyroidism, hypocalcemia, rheumatoid arthritis, myeloproliferative disorder,
gout, Paget's disease of the bone, or osteomalacia; patients with a diagnosis of
osteoporosis prior to multiple myeloma diagnosis are eligible to participate.

Key Exclusion Criteria:

- Known underlying condition that may result in abnormal bone metabolism other than
cancer related bone lesions

- History of polyneuropathy ≥ grade 3

- Patients with plasma cell leukemia

- Planned stem cell transplant (HSCT) or radiation for the duration of the study

- Skeletal related event within 2 weeks of study enrollment

- Has received erythropoiesis-stimulating agents (ESAs) within the last 21 days or is
planned to receive ESAs during the course of the study

- Has received anti-myeloma therapy within the last 21 days

- Is scheduled to receive local radiation to bone during the course of the study

- Has taken estrogen, androgen, anabolic steroids, calcitonin or other bone-active
drugs within 4 months of study enrollment

- Woman of childbearing potential (not undergone a hysterectomy or who have not been
postmenopausal for at least 24 consecutive months)